IL17 in Sarcoidosis – A level playing field?
Keywords:
Sarcoidosis, IL17, Secukinumab, Bimekizumab, Broadalumab, IxekizumabAbstract
-
References
1. England N. Clinical commissioning policy: infliximab for refractory sarcoidosis. 2023. Available from: https://www.england.nhs.uk/publication/clinical-commissioning-policy-infliximab-for-refractory-sarcoidosis/ (accessed 2024 Jul 1).
2. Nelson NC, Kogan R, Condos R, Hena KM. Emerging therapeutic options for refractory pulmonary sarcoidosis: the evidence and proposed mechanisms of action. J Clin Med 2023;13(1). doi: 10.3390/jcm13010000
3. Baker MC, Horomanski A, Wang Y, et al. A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis. Rheumatology (Oxford) 2024;63(5):1297-304. doi: 10.1093/rheumatology/keae091
4. Zhao SS, Baker MC, Galloway JB. IL-6 receptor inhibition and risk of sarcoidosis: a Mendelian randomization study. Rheumatology (Oxford) 2024;63(4):e118-9. doi: 10.1093/rheumatology/kead471
5. Ostadkarampour M, Eklund A, Moller D, et al. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren's syndrome. Clin Exp Immunol 2014;178(2):342-52. doi: 10.1111/cei.12325
6. Eichhoff G. Management with secukinumab of tumour necrosis factor inhibitor-induced pulmonary sarcoidosis-like reaction in a patient with psoriasis. Clin Exp Dermatol 2020;45(4):455-6. doi: 10.1111/ced.14117
7. Kobak S, Gungen AC, Gungen BD, Tutpinar Y, Guler M. Secukinumab in a patient with sarcoidosis. Scand J Rheumatol 2021;50(3):250-1. doi: 10.1080/03009742.2020.1828150
8. Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis 2017;11(3):378-83. doi: 10.1093/ecco-jcc/jjw168
9. Kirby C, Herlihy D, Clarke L, Mullan R. Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis. BMJ Case Rep 2021;14(2):e240140. doi: 10.1136/bcr-2020-240140
10. Nyckowski T, Ceilley R, Wilson J. Sarcoidosis developing during secukinumab therapy: case report. Skin 2017;1(2):95-9. doi: 10.25251/skin.1.2.3
11. Lu JW, Zhang MH, Gopee S, Lu Y. Cutaneous sarcoidosis after application of secukinumab in a patient with plaque psoriasis. J Dermatol 2021;48(10):e494-5. doi: 10.1111/1346-8138.16030
12. Hlaca N, Zagar T, Kastelan M, Brajac I, Prpic-Massari L. Secukinumab-induced scar sarcoidosis in a patient with plaque psoriasis. Australas J Dermatol 2022;63(2):e187-9. doi: 10.1111/ajd.13731
13. Hatipoglu D, Tanski C, Hachamovitch R, Legha S, Moudgil R. Ixekizumab-induced cardiac sarcoidosis: a case report. CJC Open 2021;3(1):118-20. doi: 10.1016/j.cjco.2020.10.015
14. Cohen Aubart F, Lhote R, Amoura A, et al. Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database. J Intern Med 2020;288(3):356-62. doi: 10.1111/joim.13077
15. UCB. Bimekizumab clinical trials. 2024. Available from: https://www.ucb.com/clinical-studies/Clinical-studies-index/bimekizumab-UCB4940 (accessed 2024 Jul 1).
16. Griffiths CEM, Gooderham M, Colombel JF, et al. Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. Dermatol Ther (Heidelb) 2022;12(6):1431-46. doi: 10.1007/s13555-022-00738-w
17. Novartis. The Cosentyx clinical trial programme. 2023. Available from: https://novartis.gcs-web.com/static-files/c411afd9-861d-4c5e-b80d-2311f088c2eb
18. Singh SK, Mahler HC, Hartman C, Stark CA. Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants? J Pharm Sci 2018;107(11):2735-41. doi: 10.1016/j.xphs.2018.04.027
19. Venhoff N, Schmidt WA, Bergner R, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol 2023;5(6):e341-50. doi: 10.1016/S2665-9913(23)00102-0
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Deepak Nagra, Hassan Choudry, Joy Odia, Akshay Balaji, Katie Bechman, Mark Russell, Maryam Adas, Zijing Yang, Chamith Rosa, Siwalik Banerjee, Tim Blake, Nicola Gullick, James Galloway
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
